Loading...
The 2023 American Society of Clinical Oncology (ASCO) annual meeting, held June 2 to 6 in Chicago, highlighted key advances in treatment across a broad spectrum of malignancies. Here, Associate Editor Dr. David Ilson reviews important trials in colorectal, gastric, and biliary tract cancers, some practice changing.
At the Plenary Session, researchers presented results from the randomized, phase 3 PROSPECT trial comparing neoadjuvant FOLFOX against chemoradiotherapy in patients with clinical stage T2N1 or T3N0–1 locally advanced mid- or high-rectal cancer who were candidates for sphincter-sparing surgery (abstract LBA2 and N Engl J Med 2023 Jun 4; [e-pub]). Patients rece…